相似文献
1
Early diagnosis of cancer using circulating microbial DNA.
Cell Rep Med. 2024 Apr 16;5(4):101502. doi: 10.1016/j.xcrm.2024.101502.
2
Leveraging circulating microbial DNA for early cancer detection.
Trends Cancer. 2023 Nov;9(11):879-882. doi: 10.1016/j.trecan.2023.08.001. Epub 2023 Sep 1.
3
Utilising extracellular vesicles for early cancer diagnostics: benefits, challenges and recommendations for the future.
Br J Cancer. 2022 Feb;126(3):323-330. doi: 10.1038/s41416-021-01668-4. Epub 2022 Jan 10.
4
How to detect cancer early using cell-free DNA.
Cancer Cell. 2022 Dec 12;40(12):1464-1466. doi: 10.1016/j.ccell.2022.11.009.
5
Circulating cell-free DNA-based multi-cancer early detection.
Trends Cancer. 2024 Feb;10(2):161-174. doi: 10.1016/j.trecan.2023.08.010. Epub 2023 Sep 14.
6
Recent advances in circulating nucleic acids in oncology.
Ann Oncol. 2019 Mar 1;30(3):374-384. doi: 10.1093/annonc/mdz031.
7
Circulating cell-free DNA-based methylation pattern in plasma for early diagnosis of esophagus cancer.
PeerJ. 2024 Jan 31;12:e16802. doi: 10.7717/peerj.16802. eCollection 2024.
8
Sensitive tumour detection and classification using plasma cell-free DNA methylomes.
Nature. 2018 Nov;563(7732):579-583. doi: 10.1038/s41586-018-0703-0. Epub 2018 Nov 14.
9
Plasma DNA for early cancer detection - opportunities and challenges.
Expert Rev Mol Diagn. 2019 Jan;19(1):5-7. doi: 10.1080/14737159.2019.1555476. Epub 2018 Dec 10.
10
The contribution of the 20th century discoveries on the circulating DNA as biomarkers for cancer screening.
An Acad Bras Cienc. 2020 Nov 16;92(4):e20200919. doi: 10.1590/0001-3765202020200919. eCollection 2020.
引用本文的文献
1
Medical laboratory data-based models: opportunities, obstacles, and solutions.
J Transl Med. 2025 Jul 24;23(1):823. doi: 10.1186/s12967-025-06802-x.
2
Predictive value of NUF2 for prognosis and immunotherapy responses in pan-cancer.
Nan Fang Yi Ke Da Xue Xue Bao. 2025 Jan 20;45(1):137-149. doi: 10.12122/j.issn.1673-4254.2025.01.17.
本文引用的文献
1
Circulating microbiome DNA as biomarkers for early diagnosis and recurrence of lung cancer.
Cell Rep Med. 2024 Apr 16;5(4):101499. doi: 10.1016/j.xcrm.2024.101499. Epub 2024 Apr 5.
2
Leveraging circulating microbiome signatures to predict tumor immune microenvironment and prognosis of patients with non-small cell lung cancer.
J Transl Med. 2023 Nov 10;21(1):800. doi: 10.1186/s12967-023-04582-w.
3
Key study of cancer microbiomes challenged.
Science. 2023 Aug 11;381(6658):590-591. doi: 10.1126/science.adk2103. Epub 2023 Aug 10.
4
Novel directions of precision oncology: circulating microbial DNA emerging in cancer-microbiome areas.
Precis Clin Med. 2022 Feb 3;5(1):pbac005. doi: 10.1093/pcmedi/pbac005. eCollection 2022 Mar.
5
The microbiome and human cancer.
Science. 2021 Mar 26;371(6536). doi: 10.1126/science.abc4552.
6
Microbiome analyses of blood and tissues suggest cancer diagnostic approach.
Nature. 2020 Mar;579(7800):567-574. doi: 10.1038/s41586-020-2095-1. Epub 2020 Mar 11.
7
Multi-Method Characterization of the Human Circulating Microbiome.
Front Microbiol. 2019 Jan 17;9:3266. doi: 10.3389/fmicb.2018.03266. eCollection 2018.
8
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine.
Science. 2017 Sep 15;357(6356):1156-1160. doi: 10.1126/science.aah5043.
Zotero 插件